Breast Cancer

Axillary ultrasound and biopsy appear to be an effective strategy to identify nodal disease in patients with early-stage triple-negative breast cancer.

The FDA approval of olaparib comes from the results of the phase 3 OlympiA trial that tested the treatment vs a placebo.

Treatment with sacituzumab govitecan-hziy in patients with hormone receptor–positive/HER2-negative metastatic breast cancer who previously received treatment with endocrine therapy, CDK4/6 inhibitors, and 2 to 4 lines of chemotherapy resulted in a statistically significant improvement in progression-free survival vs physician’s choice of chemotherapy.

In patients with postmenopausal breast cancer treated with tamoxifen and 2 to 3 years of letrozole, an additional 5-years of letrozole yielded an improvement in disease-free survival.

Compared with a wait-list control group, mindful awareness practices and survivorship education significantly reduced depressive symptoms from preintervention to postintervention in younger survivors of breast cancer.

Assessing adverse effects with a toxicity index and patient-reported outcomes at baseline and treatment-emergent toxicities revealed insights into why postmenopausal patients with ductal carcinoma in situ discontinued endocrine therapy.

Patients with stage II/III HER2-negative breast cancer who were treated with daily high-dose aspirin did not experience an improvement in invasive disease-free survival.

Advice for community physicians treating HER2+ breast cancer.

A phase 3 study from China identified that gonadotropin-releasing hormone analogs administered with chemotherapy reduced the risk of premature ovarian insufficiency among premenopausal patients with breast cancer.

Treatment with an aromatase inhibitor appears to reduce the risk of breast cancer recurrence in patients who are premenopausal and undergoing ovarian suppression vs tamoxifen.

Dr. Virginia Kaklamani discusses the role of maintenance therapies for HER2+ breast cancer.

Virginia Kaklamani, MD, DSc, provides an overview of the goals of care for HER2+ breast cancer.

Breast cancer risk was estimated among survivors of pediatric cancer who were treated with chest radiation with a newly developed and validated breast cancer risk prediction model.

The FDA has given a fast track designation to gedatolisib as a treatment for patients with hormone receptor-positive, HER2-negative metastatic breast cancer.

“If we can understand the mechanisms of resistance to be able to monitor [patients] in real time, then we will be able to turn many cases of cancer into chronic diseases.”

In this episode of "Oncology Peer Review On-The-Go," Amy Comander, MD, spoke with CancerNetwork regarding important developments in breast cancer that took place in 2021 and key clinical trials that read out throughout the year.

Patients with breast cancer who were treated at a community-based oncology practice that used routine depression screening were more likely to a receive referral for behavioral care vs those in an education-only cohort.

Enobosarm was granted fast track designation by the FDA for the treatment of patients with androgen receptor–positive, estrogen receptor–positive, HER2-negative metastatic breast cancer.

Experts provide clinical pearls to the audience on treating patients with breast cancer.

The panelists share their insights on managing toxicities and special considerations in the treatment of HER2+ breast cancer.

Amy Comander, MD, shares her thoughts on key developments in breast cancer care that took place in 2021, and reflects on what the future might hold for this patient population

Remedying gaps in knowledge and implementing strategies for financial toxicity mitigation are important for optimizing breast cancer treatment.

Patient Case 2 is presented, and Dr Gadi and Dr Mahtani detail how they would proceed with treating this patient.

Patient Case 1 is presented to the panel, and Vijayakrishna Gadi, MD, PhD, shares his thoughts on how to approach treatment of this patient.

Patients with HER2-mutant breast cancer given neratinib combinations saw improved efficacy.